B.P. Pharma

What B.P. Pharma does

B.P. Pharma is an Egyptian pharmaceutical company founded in 1988 by Dr. Essam H. Dimetrios, headquartered in 6 October City, Giza. The company operates two business divisions: Neurology, comprising six prescription products including Citicoline-Life, Cerebrolysin, Convulex (valproic acid), Neurotop (carbamazepine), Lidemtzil (donepezil ODT for Alzheimer's), and Zolmigo (zolmitriptan ODT for migraine); and Cosmeceuticals, with over 80 products spanning body care, facial care, hair care, dermatology, gynecology, pediatrics, oral care, and orthopedics. B.P. Pharma distributes and markets products on behalf of European principals — Gerot Lannach (Austria, since 1993), Biosyn (Germany, since 1993), and Ever Pharma (Austria, since 1994) — for the Egyptian and regional markets.

The company generates revenue through pharmaceutical importation, distribution, and marketing, plus toll manufacturing via three wholly-owned subsidiaries: Life Company and Resurrection Company (both established 2011 for local registration and manufacturing of generics and cosmeceuticals, contributing 38 and 34 registered cosmeceutical products respectively), and Maple Pharma (acquired February 2019 as a manufacturing facility with 10,280 sqm of land area in the 6th of October industrial zone). The go-to-market is traditional sales-led, deploying medical representatives to clinicians, pharmacists, and hospitals across Egypt, with stated expansion ambitions across African countries, UK, UAE/GCC, the Middle East, and South America. Pricing is not publicly disclosed and operates on quote-based terms typical of prescription and consumer health products.

Ownership is concentrated in the founding Dimetrios family, with the founder serving as CEO across the parent and all three subsidiaries, and family members occupying Deputy General Manager (Operations & Sales), Deputy General Manager (Operations & Marketing), and Business Development & Supply Chain Manager positions. The company is privately held with no disclosed external investors, parent entity, or public listing. The multilingual website (Arabic, English, French, German, Italian, Spanish, Chinese) and standard social media presence (Facebook, Twitter, YouTube, newsletter) constitute the entirety of its digital footprint, with no AI, API, or platform technology components disclosed.

Name

B.P. Pharma

Legal name

B.P. Pharma

Website

https://bppharma.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

51–100 employees

Short description

B.P. Pharma is a privately held Egyptian pharmaceutical company, founded 1988, that distributes and manufactures neurology prescription products and over 80 cosmeceutical SKUs through three subsidiaries, serving clinicians, pharmacies, hospitals, and consumers in Egypt and selected international markets.

Ownership category

akta.pro rank

Product category

Neurology Pharmaceuticals and Cosmeceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Pharmaceutical distribution
• Neurology medications
• Cosmeceutical products
• Pharmaceutical manufacturing
• Egyptian pharmaceuticals

Headquarters

HQ city

6 October City

HQ country

Egypt

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Distribution: B.P. Pharma generates revenue through importing, distributing, and marketing pharmaceutical products, particularly neurological medications and cosmeceuticals. The company also manufactures products through its subsidiary Maple Pharma.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

B.P. Pharma imports, distributes, markets, and promotes pharmaceutical products in Egypt and regional markets, with a primary focus on neurological medications (treating Parkinson's disease, Alzheimer's dementia, epilepsy, stroke, migraine, and traumatic brain injury) sourced through partnerships with European pharmaceutical companies. The company also manufactures and sells a portfolio of cosmeceutical products spanning skincare, dermatology, gynecology, pediatrics, oral care, and orthopedics through its subsidiaries Life, Resurrection, and Maple Pharma.

Product overview

B.P. Pharma is an Egyptian pharmaceutical company founded in 1988 by Dr. Essam H. Dimetrios. The company operates two main therapeutic areas: Neurology and Cosmeceuticals. The Neurology portfolio includes six main products: Citicoline-Life (cognitive disorder injection), Zolmigo 2.5mg ODT (migraine treatment), Cerebrolysin (neurotrophic peptide drug), Convulex (valproic acid for epilepsy/bipolar), Neurotop (carbamazepine for epilepsy/neuralgia), and Lidemtzil (donepezil ODT for Alzheimer's). The Cosmeceuticals division encompasses over 80 products across six subcategories: Body Cosmetics (shower gels, soaps, creams, hand wash), Facial Cosmetics (facial washes, wet wipes, creams), Hair Care (shampoos, serums, lotions), Dermatology (acne treatments, anti-dandruff, skin whitening, sun care with SPF 50+), Gynecology (intimate washes, dilution gels, wet wipes), Pediatrics (lotions, creams), Oral Care (mouth wash, toothpaste), and Orthopedics (massaging creams, ointments, sprays). The company also operates manufacturing through Maple Pharma and maintains partnerships with European pharmaceutical companies including Ever Pharma (Austria), Gerot Lannach (Austria), and Biosyn (Germany).

Differentiator

Problem solved

Functional benefit

Products and services

• Citicoline – Life

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core.

• Maple PharmacoreStrategic or Co-development Partner · 1 January 2019Maple Pharma is B.P. Pharma's manufacturing facility acquired in February 2019 (formerly PAUL HARTMANN GERMANY- EGYPT) located in 6th of October industrial zone. Land area of 10,280 sqm with potential for pharmaceutical and cosmeceutical production. Features R&D center development plans.
• Life CompanycoreStrategic or Co-development Partner · 1 January 2011Life is B.P. Pharma's daughter company established in 2011 for locally registering and manufacturing generic pharmaceutical products, food supplements, and developing new diversified products. Portfolio includes 38 registered cosmeceutical products and unique product Lidemtzil ODT.
• Resurrection CompanycoreStrategic or Co-development Partner · 1 January 2011Resurrection is a subsidiary established in 2011 for local registration and manufacturing of generic pharmaceutical products, food supplements, and new product development. Portfolio includes 34 registered cosmeceutical products across cosmetics, dermatology, gynecology, oral care, orthopedics, and pediatrics.
• Ever Pharma GmbHcoreStrategic or Co-development Partner · 1 January 1994Ever Pharma GmbH (formerly Ebewe Pharma) is an Austrian pharmaceutical company founded in 1934, specializing in neurodegenerative and cerebrovascular diseases. They produce parenteral medicines and neuro-products. B.P. Pharma partnered with Ever Pharma in 1994 for neuro-products distribution in Egypt.
• Gerot Lannach GmbHcoreStrategic or Co-development Partner · 1 January 1993Gerot Lannach GmbH is an Austrian pharmaceutical company with over 60 years of experience in developing and selling human healthcare products. Core competencies include epilepsy, gynecology, and angiology. They are recognized internationally and highly esteemed in specialist circles.

Scale indicators3 records

Recent moves13 records

Expansion highlights5 records

Others

• Ever Pharma GmbH: Austrian pharmaceutical company specializing in neurodegenerative and cerebrovascular injectable products. Comparable as one of B.P. Pharma's three core European principal partners supplying the neurology portfolio, and structurally similar on neuro-product focus.

Direct peers

• Pharco Pharmaceuticals: One of the largest Egyptian pharmaceutical manufacturers with branded generics and specialty products across MENA. Comparable to B.P. Pharma on Egyptian manufacturing base, branded pharma focus, and regional distribution.
• Acdima (Arab Company for Drug Industries and Medical Appliances): Jordanian/Arab pharmaceutical manufacturer with branded generics across the MENA region. Comparable on regional manufacturing, branded pharma portfolio, and export distribution across the same geographies B.P. Pharma targets.
• EIPICO (Egyptian International Pharmaceutical Industries Company): Major Egyptian pharmaceutical manufacturer producing branded and generic drugs across multiple therapeutic areas. Direct peer on Egyptian manufacturing, multi-therapeutic portfolio, and regional export orientation.
• EVA Pharma: Egyptian-headquartered pharmaceutical company with branded generics and specialty pharma portfolio across MENA and Africa. Directly comparable to B.P. Pharma on Egyptian domicile, multi-country MENA presence, branded + generics model, and toll-manufacturing footprint.
• Amoun Pharmaceutical: Egyptian pharmaceutical manufacturer with a portfolio spanning human and animal health. Comparable to B.P. Pharma on Egyptian manufacturing base, branded pharma distribution, and MENA regional presence.

Regional players

• Saudi Egyptian Pharmaceutical Company (Sephco): Joint Saudi-Egyptian pharmaceutical manufacturer with branded generics serving MENA. Comparable on Egyptian manufacturing base, regional distribution, and partnership-driven growth model.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with branded generics across the GCC. Comparable as a regional MENA pharma player with manufacturing and branded portfolio, though headquartered in the Gulf rather than Egypt.
• SPIMACO Addwaeih: Saudi pharmaceutical manufacturer with branded generics and licensing partnerships across the Middle East. Comparable on the partner-distribution-plus-manufacturing model and regional MENA distribution scale.

Broad incumbents

• Hikma Pharmaceuticals: Jordan-headquartered multinational with branded generics, injectables and specialty across MENA and the US. Comparable as a regional pharma incumbent with manufacturing, MENA distribution scale much larger than B.P. Pharma, and overlapping neurology and specialty focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@B.P.Pharma-z6m
• Facebookfacebook.com/bppharma.dimetrios
• LinkedInlinkedin.com/company/bppharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about B.P. Pharma